A Phase I, Blinded, Placebo-controlled, Dose-escalation Study of the Safety and Pharmacokinetics of XOMA 3AB Administered Intravenously in Healthy Adults.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2014
At a glance
- Drugs XOMA 3AB (Primary)
- Indications Botulism
- Focus Adverse reactions
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2012 Planned End Date changed from 1 Apr 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 03 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.